Traditional, 10-Year MOC Exam
Marwan S. Ghabril, MD, Chair
Dr. Ghabril has been a transplant hepatologist for over 10 years. He is currently an associate professor of Medicine and will be submitting his dossier for promotion to professor with tenure late this year. Trained at the Mayo Clinic, Florida, he has been an integral member of the transplant team at Indiana University since 2008 and has enjoyed a busy and clinically challenging transplant practice.
His clinical experience is complemented by administrative and extensive quality work as director of an inpatient liver service. He serves on multiple multidisciplinary committees for safety, quality and utilization. Dr. Ghabril serves as a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology.
Dr. Ghabril received his medical degree from the Royal College of Surgeons in Ireland, completed his residency at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, and completed fellowships at Mayo Clinic.
As of May 2024, Dr. Ghabril reported the following ongoing external relationships:
Funding for clinical trial expenses and staff, paid to Indiana University, from the following companies:
- Salix, for a hepatic encephalopathy trial
Service on data and safety monitoring boards for the following companies, with honoraria:
- ACTC
- Biocryst
- CymaBay
- PTC Therapeutics
- Zydus
Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:
- The Liver Research Consortium
Dr. Ghabril serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Association for the Study of Liver Diseases, Practice Metric Committee, member, without compensation
Dr. Ghabril also serves on two data and safety monitoring boards for two National Institutes of Health-funded studies.
Andrew Keaveny, MD
Dr. Keaveny is a Consultant Hepatologist in the Departments of Transplant and Internal Medicine and Medical Director of the Liver Transplant Program at the Mayo Clinic in Jacksonville, Florida. He is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and Science and board certified in Gastroenterology and Transplant Hepatology.
Previously, Dr. Keaveny was a member of the Section of Gastroenterology in the Department of Medicine at Boston University Medical Center.
Dr. Keaveny has served as a member of the American Board of Internal Medicine Test & Policy Committee on Transplant Hepatology and the Item-Writing Task Force. He joined the Transplant Hepatology Traditional, 10-Year MOC Exam Approval Committee in 2023. He has served on several committees in the American Association for the Study of Liver Diseases and was Chair of the Education Committee from 2015 to 2017. He was a member of the Liver and Intestine Advisory Council of the American Society of Transplantation from 2008 to 2012. He was the Program Director for the Transplant Hepatology Fellowship at Mayo Clinic Florida (MCF) from 2008 to 2013. He has received awards for teaching from the MCF Division of Gastroenterology and Hepatology as well as the Internal Medicine Residency Program. He was recognized for his contributions to the Transplant Hepatology Fellowship by receiving the Outstanding Course Director Award in 2008 from the Mayo School of Continuous Professional Development. He is on the editorial boards of Hepatology, Liver Transplantation and Annals of Hepatology. He served as an Associate Editor of Clinical Liver Disease from 2011 to 2017. He is the author or co-author of more than 60 peer-reviewed publications and edited the book, “Complications of Cirrhosis: Evaluation and Management” (2015).
Dr. Keaveny received his medical degree from University College Dublin in Ireland. He completed internal medicine residencies in both Dublin and Boston, and fellowships in gastroenterology and transplant hepatology at Boston University Medical Center and the Lahey Hospital & Medical Center (formerly the Lahey Clinic), respectively.
As of October 2023, Dr. Keaveny reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:
- Biovie, Inc.
- HepQuant, LLC, for a study of a liver diagnostic kit for likelihood of large esophageal varices, receiving funding for clinical trial expenses, staff and salary support
Attendance at investigators’ meetings, with compensation for travel expenses and honoraria from the following companies:
- Biovie, Inc.
- HepQuant, LLC
Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:
- Mallinckrodt
Work as an author or editor for the following companies, with compensation as listed:
- UpToDate®, receiving compensation for authorship regarding gallstone ileus
Dr. Keaveny serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Association for the Study of Liver Diseases, Online Learning Committee, member; Nominating Committee, member, without compensation
Paul Y Kwo, MD
Dr. Kwo is a Professor of Medicine and Director of Hepatology at Stanford University. He is board certified in Gastroenterology and Transplant Hepatology.
Prior to joining the faculty at Stanford, Dr. Kwo served as Medical Director of Liver Transplantation at Indiana University.
Dr. Kwo has served as a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology and joined the Transplant Hepatology Traditional, 10-Year MOC Exam Approval Committee in 2023. He is a Trustee of the American College of Gastroenterology and serves on the Clinical Research Committee for the American Association for the Study of Liver Diseases. He has won multiple awards on the university, local and national levels.
Dr. Kwo completed his undergraduate education at Oberlin College and his medical education at Wayne State University. His completed his internal medicine training at the University of Maryland Medical System and his gastroenterology and hepatology training at the Mayo Clinic.
As of October 2023, Dr. Kwo reported the following external relationships:
Funding for salary support, clinical trial expenses and staff, paid to Stanford University, from the following companies:
- Arrowhead
- Altimmune
- Fractyl
- Gilead
- Madrigal
- Novo Nordisk
- Target PhamaSolutions
- Ultragenyx
Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:
- AbbVie, for an advisory board for hepatitis therapies
- Aligos, for an advisory board
- Eiger, for an advisory board
- The CDA Foundation, for a grant review panel for viral hepatitis elimination
- Drug Farm, for an advisory board
- Galapagos, for an advisory board for hepatitis therapies
- Gilead, for an advisory board for nonalcoholic steatohepatitis, hepatitis B and hepatitis C therapies
- Inventiva, for an advisory board
- Surrozen, for an advisory board
Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:
- Gilead, for a lecture on hepatitis B management, receiving honoraria and reimbursement for travel expenses
- Indiana University, regarding hepatitis C, receiving honoraria
- Mallinckrodt, for continuing medical education symposia for AKI-HRS, receiving honoraria and reimbursement for travel expenses
Brendan M. McGuire, MD
Dr. McGuire is Medical Director of Liver Transplantation at the University of Alabama at Birmingham (UAB). He is board certified in Gastroenterology and Hepatology and Transplant Hepatology.
Brendan McGuire has been an active volunteer within and beyond the borders of Alabama. Locally Dr. McGuire is Director of the UAB Liver Transplant Fellowship Program, a member on the Steering Committee for the UAB GI Fellowship Program, a member of the School of Medicine Promotions Committee, and a member of the Liver Transplant Evaluation Committee.
Nationally he has been an active volunteer for United Network for Organ Sharing (UNOS), American Society of Transplantation (AST) and American Association for the Study of Liver Diseases (AASLD). For UNOS, he has been on the Membership and Standards Committee, the Region 3 Liver and Intestinal Representative, a Regional Review Board Member, and a National Review Board Member. For AST, Dr. McGuire has been on the Nominating Committee, AST Practice Guidelines Committee, and has chaired the Liver and Intestinal Advisory Group. For AASLD, he has been on the Acute on Chronic Liver Failure Special Interest Group and Ethics Committee.
After graduating from the University of Notre Dame in 1984 he completed a master's of science in bioengineering from Pennsylvania State University and a doctorate in medicine from the University of Pittsburgh in 1990. After completing his internal medicine residency and gastroenterology and hepatology fellowship at the University of Minnesota in 1996, he joined the faculty of UAB and has been there ever since.
As of October 2023, Dr. McGuire reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the University of Alabama-Birmingham, from the following companies:
- Alnylam
- Arrowhead
- Disc Medicine
- Grifols
Dr. McGuire serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Porphryias Expert Collaborative, Board of Directors, without compensation
Emily Perito, MD
Dr. Emily R. Perito is an associate professor at University of California San Francisco (UCSF) who specializes in pediatric liver and pancreatic disease, pediatric liver transplant, and pediatric gastroenterology. She is jointly appointed in the Departments of Pediatrics and of Epidemiology and Biostatistics. She is board-certified in Pediatrics, Pediatric Gastroenterology, and Pediatric Transplant Hepatology. Dr. Perito's clinical care and research focus on optimizing long-term outcomes for children with liver and pancreatic diseases. She is Associate Medical Director of UCSF's multi-disciplinary Pediatric Liver Transplant team with expertise in the care of children with pediatric liver disease before and in the long-term after transplant.
She leads epidemiologic research focused on improving access to transplant, organ allocation, and waitlist outcomes for children awaiting liver transplant. She is a co-Chair of the Starzl Network for Excellence in Pediatric Transplantation on improving the efficacy and reducing the burden of immunosuppression for children after liver transplant. She also advocates for children nationally as the Vice-Chair of UNOS' Pediatric Transplantation Committee and Chair of the Society for Pediatric Liver Transplant's Advocacy Committee. She is also co-Director of UCSF's Pediatric Pancreas Program. She lead's UCSF's work in National Institutes of Health-sponsored multi-center trials including the INSPPIRE study on acute recurrent and chronic pancreatitis in children and adolescents.
As of July 2023, Dr. Perito reported the following ongoing external relationships:
Funding for clinical trial expenses and staff, paid to the University of California, San Francisco, from the following companies:
- Albireo, for odevixibat pediatric clinical trials
- Alexion, for an ALNX1840 pediatric clinical trial
- Discerna, for two pediatric clinical trials
- Gilead, for a tenofovir alafenamide pediatric clinical trial
- Mirum, for a maralixibat pediatric clinical trial
Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses:
- The Scientific Registry of Transplant Recipients Review Committee
Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:
- Amagma Therapeutics, for consulting on therapeutics for chronic pancreatitis
- BridgeBio, for consulting on the use of gene therapy for treatment of metabolic diseases, the impact of treatment on the liver and immunosuppression to prevent liver damage
- Ultragenyx-BridgeBio, for consulting on the use of gene therapy for the treatment of metabolic diseases, the impact of treatment on the liver and immunosuppression to prevent liver damage
Dr. Perito serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Association for the Study of Liver Diseases, Clinical Research Committee, member; Patient Engagement Committee, member; associate editor of Liver Transplantation, without compensation
- The Autoimmune Liver Disease Network for Kids, site leader, without compensation
- The Society of Pediatric Liver Transplantation (SPLIT), Advocacy Committee, chair, without compensation
- Liver Transplantation, Associate Editor, without compensation
- The North American Society for Pediatric Gastroenterology, Hepatology & Nutrition, Publications Committee, member; The Journal of Pediatric Gastroenterology and Nutrition Editorial Board, without compensation
- The Starzl Network for Excellence in Pediatric Transplantation (SNEPT), co-chair, receiving honoraria
- The United Network for Organ Sharing, Pediatric Committee, vice-chair; Policy Oversight Committee, member, receiving reimbursement for travel expenses
Grant funding for expenses and staff, paid to the University of California, San Francisco, from the following nonprofit health care-related organizations:
- The National Institute of Diabetes and Digestive and Kidney Diseases, for improving medication adherence in adolescents who had a liver transplant; SNEPT and SPLIT implementation of a quality of life measure in pediatric transplant recipients; INSPPIRE Pediatric Pancreatitis Research Group to study chronic and acute recurrent pancreatitis in children
- The Patient-Centered Outcomes Research Institute, for patient-centered research in transplant for engaging families & recipients
Elizabeth Rand, MD
Dr. Rand joined the faculty of the University of Pennsylvania School of Medicine and the clinical staff of the Children's Hospital of Philadelphia in 1993 where she is now a professor of pediatrics and the Medical Director of the Liver Transplant Program respectively; and holds American Board of Pediatrics certification in Pediatric Gastroenterology as well as a Certificate of Added Qualification in Pediatric Advanced Transplant Hepatology. Dr. Rand is a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology.
Dr. Rand is involved in graduate medical education as a clinical faculty member and also as the Fellowship Program Director of both the Pediatric Gastroenterology (since 2000) and advanced Pediatric Hepatology (since 2010) Training Programs.
Dr. Elizabeth Rand is a graduate of the University of Chicago Pritzker School of Medicine in Illinois and completed her residency in pediatrics at the Johns Hopkins Hospital in Baltinmore, Maryland followed by her pediatric gastroentrology fellowship at the University of Chicago.
View my board certification status via ABMS Website.
As of October 2023, Dr. Rand reported the following external relationships:
Work as an author or editor for the following companies, with compensation as listed:
- The American Association for the Study of Liver Diseases, receiving compensation for role as associate editor of and continuing medical education question-writer for Clinical Liver Disease
- UpToDate®, receiving compensation for role as section editor
Dr. Rand serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Association for the Study of Liver Diseases, committee member, receiving honoraria and reimbursement for travel expenses
- The Make-a-Wish Foundation, Regional Advisory Board, member, without compensation
- The Society for Pediatric Liver Transplantation, Council, member, without compensation
- The United Network for Organ Sharing, committee member, receiving honoraria and reimbursement for travel expenses